



# Return on Investment in Needle and Syringe Programs in Australia

## Report

Return on Investment in Needle and Syringe Programs in Australia • Report



**COMMONWEALTH DEPARTMENT OF  
HEALTH AND AGEING**

RETURN ON INVESTMENT IN NEEDLE &  
SYRINGE PROGRAMS IN AUSTRALIA

REPORT

HEALTH OUTCOMES INTERNATIONAL PTY LTD

IN ASSOCIATION WITH

THE NATIONAL CENTRE FOR HIV EPIDEMIOLOGY AND  
CLINICAL RESEARCH

AND

PROFESSOR MICHAEL DRUMMOND, CENTRE OF HEALTH  
ECONOMICS, YORK UNIVERSITY

---

© Commonwealth of Australia 2002

ISBN 0 642 82116 X

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced by any process without prior written permission from the Commonwealth available from the Department of Communications, Information Technology and the Arts. Requests and inquiries concerning reproduction and rights should be addressed to the Manager, Copyright Services, Info Access, GPO Box 1920, Canberra ACT 2601.

Publication approval number: 3122

Publications Production Unit (Public Affairs, Parliamentary and Access Branch)  
Commonwealth Department of Health and Ageing

---

<b>EXECUTIVE SUMMARY</b> .....	<b>1</b>
<b>EFFECTIVENESS OF NSPs FOR PREVENTING TRANSMISSION OF HIV AND HCV INFECTION</b> .....	<b>1</b>
<b>FINANCIAL EFFECTS OF NSPs</b> .....	<b>2</b>
<b>QUALITY OF LIFE (QoL) EFFECTS OF NSPs</b> .....	<b>4</b>
<b>CONCLUSION</b> .....	<b>6</b>
<b>1 INTRODUCTION</b> .....	<b>7</b>
1.1 BACKGROUND .....	7
1.2 OBJECTIVES .....	7
1.3 METHODOLOGY.....	8
1.4 ACKNOWLEDGEMENT .....	8
<b>2 AN OVERVIEW OF NEEDLE AND SYRINGE PROGRAMS (NSPs)</b> .....	<b>9</b>
2.1 AUSTRALIA'S STRATEGIES ON HIV/AIDS AND HEPATITIS C.....	9
2.2 OVERVIEW OF NEEDLE AND SYRINGE PROGRAMS .....	9
2.3 OPERATIONS OF NEEDLE AND SYRINGE PROGRAMS.....	10
<b>3 THE IMPACT OF NSPs ON HIV AND HCV</b> .....	<b>12</b>
3.1 EFFECTIVENESS OF NSPs FOR PREVENTING TRANSMISSION OF HIV AND HCV INFECTION .....	12
3.2 METHODOLOGY FOR ESTIMATES OF NUMBERS OF PEOPLE LIVING WITH HIV ACQUIRED THROUGH INJECTING DRUGS.....	25
3.3 METHODOLOGY FOR ESTIMATES OF NUMBERS OF PEOPLE LIVING WITH HCV ACQUIRED THROUGH INJECTING DRUGS.....	27
3.4 NUMBER OF HIV INFECTIONS PREVENTED THROUGH THE INTRODUCTION OF NSPs.....	29
3.5 NUMBER OF HCV INFECTIONS PREVENTED THROUGH THE INTRODUCTION OF NSPs .....	30
<b>4 FINANCIAL EFFECTS OF NSPs</b> .....	<b>31</b>
4.1 DESCRIPTION OF THE ECONOMIC MODEL.....	31
4.2 EXPENDITURE ON NSPs.....	32
4.3 IMPACTS OF NSPs ON HIV AND HCV .....	33
4.4 METHODOLOGY FOR HEALTH CARE COSTINGS FOR HIV .....	36
4.5 METHODOLOGY FOR HEALTH CARE COSTINGS FOR HCV INFECTION .....	38
4.6 HIV TREATMENT COSTS .....	39
4.7 RETURN ON INVESTMENT.....	42
4.8 SENSITIVITY ANALYSIS.....	44
4.9 DISCUSSION.....	45
<b>5 QUALITY OF LIFE (QoL) EFFECTS OF NSPs</b> .....	<b>47</b>
5.1 INTRODUCTION.....	47
5.2 QUALITY-ADJUSTED LIFE-YEARS (QALYs).....	48

---

---

5.3	METHODOLOGY FOR ESTIMATING THE QALYS GAINED FROM THE PREVENTION OF HIV AND HCV INFECTIONS.....	48
5.4	NUMBER OF CASES OF HIV AND HCV AVOIDED .....	50
5.5	NUMBER OF LIFE YEARS GAINED .....	50
5.6	QUALITY ADJUSTED LIFE YEARS GAINED .....	52
5.7	SENSITIVITY ANALYSIS.....	55
5.8	DISCUSSION.....	56
<b>APPENDICES</b>		
APPENDIX A	OVERVIEW OF STATE AND TERRITORY NEEDLE AND SYRINGE PROGRAMS .....	57
APPENDIX B	DISCUSSION OF THE METHODOLOGY USED IN THE ECOLOGICAL STUDY .....	73
APPENDIX C	DETAILED TABLES OF EFFECTS OF NSPs ON HIV AND HCV.....	75
APPENDIX D	DETAILED TABLES ON FINANCIAL EFFECTS AND NPV OF NSPs .....	105
APPENDIX E	DETAILED TABLES ON QUALITY OF LIFE EFFECTS OF NSPs .....	125
APPENDIX F	REFERENCES.....	145